novartis ag - NVSEF

NVSEF

Close Chg Chg %
105.00 -6.75 -6.43%

Pre-Market

98.25

-6.75 (6.43%)

Volume: 2.60K

Last Updated:

Nov 20, 2024, 12:09 PM EDT

Company Overview: novartis ag - NVSEF

NVSEF Key Data

Open

$102.43

Day Range

98.25 - 102.43

52 Week Range

90.24 - 123.55

Market Cap

$192.22B

Shares Outstanding

1.96B

Public Float

1.75B

Beta

0.59

Rev. Per Employee

N/A

P/E Ratio

11.38

EPS

$8.63

Yield

378.57%

Dividend

$3.75

EX-DIVIDEND DATE

Mar 7, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

121.43K

 

NVSEF Performance

1 Week
 
-5.53%
 
1 Month
 
-9.18%
 
3 Months
 
-17.44%
 
1 Year
 
7.09%
 
5 Years
 
N/A
 

NVSEF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About novartis ag - NVSEF

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NVSEF At a Glance

Novartis AG
Lichtstrasse 35
Basel, Basel-Stadt (Basle Town) 4056
Phone 41-61-324-11-11 Revenue 45.44B
Industry Pharmaceuticals: Major Net Income 14.85B
Sector Health Technology Employees 76,057
Fiscal Year-end 12 / 2024
View SEC Filings

NVSEF Valuation

P/E Current 11.38
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.102
Price to Sales Ratio 4.642
Price to Book Ratio 4.417
Price to Cash Flow Ratio 14.591
Enterprise Value to EBITDA 11.068
Enterprise Value to Sales 4.907
Total Debt to Enterprise Value 0.118

NVSEF Efficiency

Revenue/Employee 597,446.652
Income Per Employee 195,248.301
Receivables Turnover 5.593
Total Asset Turnover 0.403

NVSEF Liquidity

Current Ratio 1.155
Quick Ratio 0.931
Cash Ratio 0.547

NVSEF Profitability

Gross Margin 72.331
Operating Margin 26.116
Pretax Margin 20.106
Net Margin 32.68
Return on Assets 7.596
Return on Equity 16.165
Return on Total Capital 11.735
Return on Invested Capital 11.592

NVSEF Capital Structure

Total Debt to Total Equity 56.46
Total Debt to Total Capital 36.086
Total Debt to Total Assets 25.378
Long-Term Debt to Equity 42.93
Long-Term Debt to Total Capital 27.438
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novartis Ag - NVSEF

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
48.66B 51.63B 50.55B 45.44B
Sales Growth
+2.44% +6.10% -2.09% -10.10%
Cost of Goods Sold (COGS) incl D&A
15.12B 15.87B 15.31B 12.57B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.46B 5.43B 5.45B 8.28B
Depreciation
2.09B 1.53B 1.46B 1.27B
Amortization of Intangibles
4.38B 3.90B 3.98B 7.01B
COGS Growth
+4.82% +4.93% -3.54% -17.86%
Gross Income
33.54B 35.76B 35.24B 32.87B
Gross Income Growth
+1.41% +6.62% -1.45% -6.73%
Gross Profit Margin
+68.92% +69.27% +69.72% +72.33%
2020 2021 2022 2023 5-year trend
SG&A Expense
22.82B 24.43B 23.14B 20.79B
Research & Development
8.98B 9.54B 8.88B 8.22B
Other SG&A
13.84B 14.89B 14.25B 12.57B
SGA Growth
-1.96% +7.02% -5.28% -10.14%
Other Operating Expense
(104.00M) (269.00M) (162.00M) 209.00M
Unusual Expense
1.71B 684.00M 4.51B 3.60B
EBIT after Unusual Expense
9.11B 10.92B 7.76B 8.26B
Non Operating Income/Expense
1.02B 785.00M 1.65B 1.74B
Non-Operating Interest Income
91.00M 71.00M 379.00M 627.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
921.00M 905.00M 1.03B 873.00M
Interest Expense Growth
+2.11% -1.74% +13.92% -15.32%
Gross Interest Expense
923.00M 909.00M 1.04B 876.00M
Interest Capitalized
2.00M 4.00M 5.00M 3.00M
Pretax Income
9.21B 10.80B 8.38B 9.14B
Pretax Income Growth
+11.16% +17.31% -22.39% +9.02%
Pretax Margin
+18.92% +20.92% +16.58% +20.11%
Income Tax
1.81B 2.12B 1.42B 551.00M
Income Tax - Current - Domestic
932.00M 958.00M 617.00M 1.14B
Income Tax - Current - Foreign
1.17B 1.47B 1.45B 1.29B
Income Tax - Deferred - Domestic
137.00M (23.00M) 142.00M (355.00M)
Income Tax - Deferred - Foreign
(430.00M) (286.00M) (797.00M) (1.52B)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
8.07B 24.02B 6.96B 8.57B
Minority Interest Expense
- (1.00M) (3.00M) 4.00M
Net Income
8.07B 24.02B 6.96B 8.57B
Net Income Growth
+13.02% +197.58% -71.05% +23.19%
Net Margin Growth
+16.59% +46.53% +13.76% +18.86%
Extraordinaries & Discontinued Operations
- - - 6.28B
-
Discontinued Operations
- - - 6.28B
-
Net Income After Extraordinaries
8.07B 24.02B 6.96B 14.85B
Preferred Dividends
- - - -
-
Net Income Available to Common
8.07B 24.02B 6.96B 14.85B
EPS (Basic)
3.545 10.7112 3.1886 7.1504
EPS (Basic) Growth
+15.34% +202.15% -70.23% +124.25%
Basic Shares Outstanding
2.28B 2.24B 2.18B 2.08B
EPS (Diluted)
3.5157 10.6288 3.1657 7.0985
EPS (Diluted) Growth
+15.79% +202.32% -70.22% +124.23%
Diluted Shares Outstanding
2.30B 2.26B 2.20B 2.09B
EBITDA
17.28B 17.03B 17.71B 20.14B
EBITDA Growth
+8.58% -1.46% +3.98% +13.75%
EBITDA Margin
+35.52% +32.99% +35.04% +44.33%

Novartis Ag in the News